Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
I-Tech AB (ITECH.ST)
Mölndal, SE
I-Tech AB, a biotechnology firm established in Mölndal, Sweden, in 2000, focuses on creating and commercializing products to prevent biofouling. Their flagship innovation is Selektope, a unique bio-repellent ingredient engineered for marine coatings. This compound provides crucial protection against hard fouling on ships, primarily by temporarily stimulating the swimming behavior of barnacle larvae, thereby preventing them from attaching to coated surfaces. The company's primary clientele is the marine coatings industry.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.57% | -4.90% | +26.73% | +40.82% | -8.68% | +15.43% | -38.51% | -16.31% | -13.75% | +151.72% | +151.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-6.3% Q1'26: -7.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-15.2% Q1'26: +11.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+33.0% ★ Q1'26: +16.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+26.5% ★ Q1'26: +37.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+134.9% ★ Q1'26: +186.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.4% ★ Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
45.57M
est: 44.00M (+3.6%)
|
52.82M
est: 59.00M (-10.5%)
|
52.90M
est: 54.00M (-2.0%)
|
83.63M
est: 74.00M (+13.0%)
|
120.86M
est: 129.00M (-6.3%)
|
179.45M
est: 164.00M (+9.4%)
|
168.12M
est: 174.00M (-3.4%)
|
197.00M
194.46M – 202.09M
+13.2% YoY
|
236.41M
230.86M – 247.49M
+20.0% YoY
|
283.69M
283.53M – 283.84M
+20.0% YoY
|
| EBITDA |
-1.66M
est: 7.54M (-122.0%)
|
3.02M
est: 10.11M (-70.1%)
|
1.60M
est: 9.26M (-82.7%)
|
18.06M
est: 12.69M (+42.4%)
|
30.35M
est: 22.11M (+37.2%)
|
54.31M
est: 35.94M (+51.1%)
|
49.74M
est: 38.13M (+30.4%)
|
43.18M
42.62M – 44.29M
+13.2% YoY
|
51.81M
50.60M – 54.24M
+20.0% YoY
|
62.17M
62.14M – 62.21M
+20.0% YoY
|
| EBIT |
-6.78M
est: 4.20M (-261.5%)
|
-5.75M
est: 5.63M (-202.1%)
|
-3.18M
est: 5.15M (-161.8%)
|
13.44M
est: 7.06M (+90.4%)
|
25.49M
est: 12.30M (+107.2%)
|
49.21M
est: 27.91M (+76.3%)
|
44.59M
est: 29.61M (+50.6%)
|
33.53M
33.09M – 34.39M
+13.2% YoY
|
40.23M
39.29M – 42.12M
+20.0% YoY
|
48.28M
48.25M – 48.31M
+20.0% YoY
|
| Net Income |
8.43M
est: -7.15M (+217.9%)
|
-4.81M
est: -1.79M (-169.1%)
|
-2.65M
est: 10.48M (-125.3%)
|
10.62M
est: 42.28M (-74.9%)
|
20.20M
est: 26.56M (-23.9%)
|
39.01M
est: 33.88M (+15.2%)
|
33.19M
est: 35.93M (-7.6%)
|
44.61M
43.39M – 45.84M
+24.2% YoY
|
64.82M
63.48M – 66.16M
+45.3% YoY
|
90.43M
88.17M – 92.69M
+39.5% YoY
|
| SGA |
11.19M
est: 8.96M (+24.9%)
|
10.50M
est: 12.02M (-12.6%)
|
10.19M
est: 11.00M (-7.3%)
|
12.28M
est: 15.07M (-18.5%)
|
31.12M
est: 26.28M (+18.4%)
|
39.95M
est: 26.88M (+48.6%)
|
—
est: 28.52M (-100.0%)
|
32.29M
31.88M – 33.13M
+13.2% YoY
|
38.75M
37.84M – 40.57M
+20.0% YoY
|
46.50M
46.48M – 46.53M
+20.0% YoY
|
| EPS |
0.71
est: -0.60 (+218.3%)
|
-0.40
est: -0.15 (-166.7%)
|
-0.22
est: 0.88 (-125.0%)
|
0.89
est: 3.55 (-74.9%)
|
1.70
est: 2.23 (-23.8%)
|
3.27
est: 2.83 (+15.4%)
|
2.78
est: 3.01 (-7.5%)
|
3.73
3.63 – 3.83
+24.2% YoY
|
5.42
5.31 – 5.53
+45.3% YoY
|
7.50
7.37 – 7.75
+38.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 201.1K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Markus Jönsson | Chief Executive officer | 3M | male |
| Magnus Henell | Chief Financial Officer & Director of Operations | 779.0K | male |
| Cecilia Ohlauson | Director of Regulatory Affairs & Sustainability | — | — |
| Per Svensson | Sales & Marketing Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ITECH.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
